Organization | Maruho Co., Ltd.

Maruho Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Osaka Japan (1915)

Organization Overview

First Clinical Trial

2008

NCT00980629

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Maruho Co., Ltd. | Maruho Europe Limited | Maruho Europe Ltd | Maruho North America Inc.

Active Ingredients

Drugs in Phase 4 Trials (3)

clindamycin (cleocin) (2 trials)

erythromycin (ilosone) (2 trials)

ethanol (1 trial)

Drugs in Phase 3 Trials (3)

asp2151 (8 trials)

pefcalcitol (9 trials)

valaciclovir (Valtrex) (1 trial)

Drugs in Phase 2 Trials (2)

calcipotriene (dovonex) (1 trial)

m516102 (1 trial)

Drugs in Phase 1 Trials (7)

bupropion (wellbutrin) (1 trial)

cyclosporine (sandimmune) (1 trial)

midazolam (versed) (1 trial)

montelukast (singulair) (1 trial)

ritonavir (Norvir) (1 trial)

sodium chloride (2 trials)

sodium monododecyl sulfate (2 trials)

Drugs in Other Trials (3)

clobetasol (dermovate) (1 trial)

lipopolysaccharide (1 trial)

prednisolone (hydeltra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acne Vulgaris (Phase 4)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Herpes Simplex (Phase 3)

Herpes Zoster (Phase 3)

Pruritus (Phase 2)

Psoriasis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 20
# of Trial APIs: 18